LABTHealthcare · Biotechnology

LABT Stock Forecast: Lakewood-Amedex Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 12 Oct 2026

$0.73

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 12 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$1.9M

Ticker Nerd rank

21 / 100

Median analyst target

$12

Analysts covering

Revenue$0.0

Operating income−$3.8M

Net income−$3.8M

Free cash flow−$2.1M

Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown

Ticker Nerd rank

LABT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lakewood-Amedex Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Oct 2026

21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Issuance

Accruals

Revisions

Quality

Growth

Momentum

Value

Volatility

Size (99): Smaller than most of the companies we track.

Volatility (1): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LABT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LABT, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LABT appears on the weeks it earns a place.

Estimates

LABT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Lakewood-Amedex Biotherapeutics, Inc. (LABT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.3×
Price / sales: —
Price / book: 0.4×
EV / EBITDA: 0.4×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −402.8%
Return on assets: −139.4%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lakewood-Amedex Biotherapeutics, Inc. (LABT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Lakewood-Amedex Biotherapeutics, Inc. has a market value of $1.9M and an enterprise value of −$2.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$7.3M.
Free cash flow in the twelve months to 30 June 2026: −$3.5M.
Shares outstanding: 2.2M.
Trailing P/E: −0.3×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lakewood-Amedex Biotherapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Oct 2026

Data provided by Twelve Data

Peers

LABT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
LABTLakewood-Amedex Biotherapeutics, Inc.	$1.9M	21
ARTLArtelo Biosciences, Inc.	$1.7M	17
OGENOragenics, Inc.	$1.9M	10
HELPHelus Pharma, Inc.	$1.5M	—
GNPXGenprex, Inc.	$2.2M	10
CRISCuris, Inc.	$1.3M	37
MLECMoolec Science SA	$1.3M	4

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lakewood-Amedex Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LABT news & analysis

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

PRNewsWire · 7 Oct 2026positive

Lakewood-Amedex announced positive preclinical data for Bisphosphocin compounds in urinary tract and pulmonary infection indications. In rodents infected with E. coli, intravesical Nu-8 administration demonstrated up to 97% inhibition.

Why it matters — The announcement reports preclinical findings for LABT’s Bisphosphocin compounds in infection indications.

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

PRNewsWire · 1 Oct 2026neutral

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) announced that CEO Kelvin Cooper, Ph.D. will participate in conferences in October. The company is a clinical-stage biotechnology firm developing a class of broad-spectrum antimicrobials called the Bisphosphocin class.

Why it matters — A LABT watcher would care because CEO participation at conferences may provide visibility into the company's clinical-stage antimicrobial pipeline and its investor outreach.

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

PRNewsWire · 28 Sept 2026positive

Lakewood-Amedex Biotherapeutics announced positive Minimum Inhibitory Concentration (MIC) data for its lead clinical candidate Nu-3, a topically formulated Bisphosphocin antimicrobial, against recent clinical isolates from infected diabetic foot ulcers.

Why it matters — This positive MIC data suggests Nu-3 shows effectiveness against clinically relevant infection isolates, a key development milestone for a LABT watcher following the company's lead candidate.

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

PRNewsWire · 24 Sept 2026positive

Lakewood-Amedex Biotherapeutics announced that the first patient has been dosed in its Phase 2a clinical trial of Nu-3 for treating mildly infected diabetic foot ulcers, marking a significant clinical development milestone for Nu-3 and its Bisphosphocin antimicrobial platform. Topline data is expected in the first quarter of 2027.

Why it matters — The dosing initiation advances a key clinical-stage program for LABT's proprietary Bisphosphocin antimicrobial platform and sets up an upcoming data readout in Q1 2027.

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

PRNewsWire · 21 Sept 2026positive

Lakewood-Amedex Biotherapeutics CEO issued a letter to shareholders highlighting recent developments, including the company's Nasdaq listing under LABT, a $7.5 million private placement, positive preclinical safety and tolerability data supporting dose selection for the Phase 2a trial of Nu-3 Gel in infected diabetic foot ulcers, and the announcement of diabetic foot expert David G. Armstrong.

Why it matters — A LABT watcher would care because the letter outlines milestones—Nasdaq listing, financing, and preclinical progress toward the Nu-3 Phase 2a trial—that shape the company's near-term clinical and corporate trajectory.

FAQ

Frequently asked questions about LABT stock

How does Ticker Nerd's model rank LABT?

As at 12 Oct 2026, Lakewood-Amedex Biotherapeutics, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

What is the LABT stock forecast for 2030?

No analyst covering Lakewood-Amedex Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LABT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

What does Lakewood-Amedex Biotherapeutics, Inc. do?

Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antimicrobial therapies for infectious diseases.

What is the latest news on LABT?

The most recent item we track (PRNewsWire, 7 Oct 2026): "Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds". Lakewood-Amedex announced positive preclinical data for Bisphosphocin compounds in urinary tract and pulmonary infection indications. In rodents infected with E. coli, intravesical Nu-8 administration demonstrated up to 97% inhibition.

Company

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antimicrobial therapies for infectious diseases. Its current pipeline centers on the Bisphosphocin class, a novel group of broad-spectrum antimicrobials designed to address infections affecting the skin, bladder, lungs, and other serious bacterial conditions. The company’s lead program, Nu-3, is a topical antimicrobial being developed for infected diabetic foot ulcers, reflecting its emphasis on localized treatment options for hard-to-treat infections. Lakewood-Amedex Biotherapeutics also works on broader anti-infective applications aimed at antibiotic-resistant pathogens, positioning the company within the specialized biotechnology segment of the healthcare market. Headquartered in University Park, Florida, the company operates as a focused developer of next-generation antimicrobial products for unmet medical needs.

CEO Dr. Kelvin Cooper Ph.D. · 5 employees · United States · https://lakewoodamedex.com